A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1− IL-2–Secreting Central Memory CellsThe Journal of Immunology, 2013
- DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical TrialPLOS ONE, 2013
- Prospects for Tuberculosis EliminationAnnual Review of Public Health, 2013
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialThe Lancet, 2013
- A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunityVaccine, 2012
- The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in AdultsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Eliminating human tuberculosis in the twenty-first centuryJournal of The Royal Society Interface, 2007
- Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma InterferonInfection and Immunity, 2007
- Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccinationJournal of Immunological Methods, 2007
- Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus ImmunityJournal of Virology, 2003